Table 1. Rare Kidney Diseases Treatment Market Size & CAGR: China VS Global, (US$ Million), 2019-2030

Table 2. Rare Kidney Diseases Treatment Market Restraints

Table 3. Rare Kidney Diseases Treatment Market Trends

Table 4. Rare Kidney Diseases Treatment Industry Policy

Table 5. Global Rare Kidney Diseases Treatment Revenue by Company (2019-2024) & (US$ million)

Table 6. Global Rare Kidney Diseases Treatment Revenue Market Share by Company (2019-2024)

Table 7. Global Rare Kidney Diseases Treatment Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Rare Kidney Diseases Treatment Mergers & Acquisitions, Expansion Plans

Table 9. Global Rare Kidney Diseases Treatment Manufacturers Product Type

Table 10. China Rare Kidney Diseases Treatment Revenue by Company (2019-2024) & (US$ million)

Table 11. China Rare Kidney Diseases Treatment Revenue Market Share by Company (2019-2024)

Table 12. Global Key Players of Rare Kidney Diseases Treatment Upstream (Raw Materials)

Table 13. Global Rare Kidney Diseases Treatment Typical Customers

Table 14. Rare Kidney Diseases Treatment Typical Distributors

Table 15. By Drug Class, Global Rare Kidney Diseases Treatment Revenue & CAGR, 2019 VS 2024 VS 2030, US$ Million

Table 16. By Distribution Channel, Global Rare Kidney Diseases Treatment Revenue & CAGR, 2019 VS 2024 VS 2030, US$ Million

Table 17. By Region, Global Rare Kidney Diseases Treatment Market Size, 2019 VS 2024 VS 2030, US$ Million

Table 18. By Region, Global Rare Kidney Diseases Treatment Revenue, 2019-2030, US$ Million

Table 19. By Country, Global Rare Kidney Diseases Treatment Revenue & CAGR，2019 VS 2024 VS 2030, US$ Million

Table 20. By Country, Global Rare Kidney Diseases Treatment Revenue, 2019-2030, US$ Million

Table 21. By Country, Global Rare Kidney Diseases Treatment Revenue Market Share, 2019-2030

Table 22. Calliditas Therapeutics AB Company Information, Head Office, Market Area and Industry Position

Table 23. Calliditas Therapeutics AB Company Profile and Main Business

Table 24. Calliditas Therapeutics AB Rare Kidney Diseases Treatment Models, Specifications and Application

Table 25. Calliditas Therapeutics AB Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 26. Calliditas Therapeutics AB Recent Developments

Table 27. GSK plc Company Information, Head Office, Market Area and Industry Position

Table 28. GSK plc Company Profile and Main Business

Table 29. GSK plc Rare Kidney Diseases Treatment Models, Specifications and Application

Table 30. GSK plc Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 31. GSK plc Recent Developments

Table 32. Aurinia Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position

Table 33. Aurinia Pharmaceuticals, Inc. Company Profile and Main Business

Table 34. Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application

Table 35. Aurinia Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 36. Aurinia Pharmaceuticals, Inc. Recent Developments

Table 37. Amicus Therapeutics, Inc. Company Information, Head Office, Market Area and Industry Position

Table 38. Amicus Therapeutics, Inc. Company Profile and Main Business

Table 39. Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application

Table 40. Amicus Therapeutics, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 41. Amicus Therapeutics, Inc. Recent Developments

Table 42. Shire (Takeda Pharmaceutical Company Limited) Company Information, Head Office, Market Area and Industry Position

Table 43. Shire (Takeda Pharmaceutical Company Limited) Company Profile and Main Business

Table 44. Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Models, Specifications and Application

Table 45. Shire (Takeda Pharmaceutical Company Limited) Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 46. Shire (Takeda Pharmaceutical Company Limited) Recent Developments

Table 47. Sanofi Company Information, Head Office, Market Area and Industry Position

Table 48. Sanofi Company Profile and Main Business

Table 49. Sanofi Rare Kidney Diseases Treatment Models, Specifications and Application

Table 50. Sanofi Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 51. Sanofi Recent Developments

Table 52. Advicenne Company Information, Head Office, Market Area and Industry Position

Table 53. Advicenne Company Profile and Main Business

Table 54. Advicenne Rare Kidney Diseases Treatment Models, Specifications and Application

Table 55. Advicenne Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 56. Advicenne Recent Developments

Table 57. Alexion Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position

Table 58. Alexion Pharmaceuticals, Inc. Company Profile and Main Business

Table 59. Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application

Table 60. Alexion Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 61. Alexion Pharmaceuticals, Inc. Recent Developments

Table 62. Horizon Therapeutics plc Company Information, Head Office, Market Area and Industry Position

Table 63. Horizon Therapeutics plc Company Profile and Main Business

Table 64. Horizon Therapeutics plc Rare Kidney Diseases Treatment Models, Specifications and Application

Table 65. Horizon Therapeutics plc Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 66. Horizon Therapeutics plc Recent Developments

Table 67. Otsuka Pharmaceutical Co., Ltd. Company Information, Head Office, Market Area and Industry Position

Table 68. Otsuka Pharmaceutical Co., Ltd. Company Profile and Main Business

Table 69. Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Models, Specifications and Application

Table 70. Otsuka Pharmaceutical Co., Ltd. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 71. Otsuka Pharmaceutical Co., Ltd. Recent Developments

Table 72. Reata Pharmaceuticals, Inc. Company Information, Head Office, Market Area and Industry Position

Table 73. Reata Pharmaceuticals, Inc. Company Profile and Main Business

Table 74. Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Models, Specifications and Application

Table 75. Reata Pharmaceuticals, Inc. Rare Kidney Diseases Treatment Revenue and Gross Margin, 2019-2024

Table 76. Reata Pharmaceuticals, Inc. Recent Developments

List of Figure

Figure 1. Rare Kidney Diseases Treatment Picture

Figure 2. Global Rare Kidney Diseases Treatment Industry Market Size and Forecast (US$ million) & (2019-2030)

Figure 3. China Rare Kidney Diseases Treatment Revenue and Forecast (US$ million) & (2019-2030)

Figure 4. 2019-2030 China Rare Kidney Diseases Treatment Market Share of Global

Figure 5. Global Rare Kidney Diseases Treatment Key Participants, Market Share, 2022 VS 2023 VS 2024

Figure 6. Global Rare Kidney Diseases Treatment Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2019-2024

Figure 7. China Rare Kidney Diseases Treatment Key Participants, Market Share, 2022 VS 2023 VS 2024

Figure 8. China Rare Kidney Diseases Treatment Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2019-2024

Figure 9. Rare Kidney Diseases Treatment Industry Chain

Figure 10. Enzyme Replacement Therapy

Figure 11. Monoclonal Antibodies

Figure 12. Others

Figure 13. By Drug Class, Global Rare Kidney Diseases Treatment Revenue, 2019-2030, US$ Million

Figure 14. By Drug Class, Global Rare Kidney Diseases Treatment Revenue Market Share, 2019-2030

Figure 15. Hospital Pharmacies

Figure 16. Retail Pharmacies

Figure 17. Online Sales

Figure 18. By Distribution Channel, Global Rare Kidney Diseases Treatment Revenue, 2019-2030, US$ Million

Figure 19. By Distribution Channel, Global Rare Kidney Diseases Treatment Revenue Market Share, 2019-2030

Figure 20. By Region, Global Rare Kidney Diseases Treatment Revenue Market Share, 2019-2030

Figure 21. North America Rare Kidney Diseases Treatment Revenue & Forecasts, 2019-2030, US$ Million

Figure 22. By Country, North America Rare Kidney Diseases Treatment Revenue Market Share, 2019-2024

Figure 23. Europe Rare Kidney Diseases Treatment Revenue & Forecasts, 2019-2030, US$ Million

Figure 24. By Country, Europe Rare Kidney Diseases Treatment Revenue Market Share, 2019-2024

Figure 25. Asia Pacific Rare Kidney Diseases Treatment Revenue & Forecasts, 2019-2030, US$ Million

Figure 26. By Country/Region, Asia Pacific Rare Kidney Diseases Treatment Revenue Market Share, 2019-2024

Figure 27. South America Rare Kidney Diseases Treatment Revenue & Forecasts, 2019-2030, US$ Million

Figure 28. By Country, South America Rare Kidney Diseases Treatment Revenue Market Share, 2019-2024

Figure 29. Middle East & Africa Rare Kidney Diseases Treatment Revenue & Forecasts, 2019-2030, US$ Million

Figure 30. U.S. Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 31. By Company, U.S. Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 32. By Drug Class, U.S. Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 33. By Distribution Channel, U.S. Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 34. Europe Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 35. By Company, Europe Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 36. By Drug Class, Europe Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 37. By Distribution Channel, Europe Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 38. China Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 39. By Company, China Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 40. By Drug Class, China Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 41. By Distribution Channel, China Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 42. Japan Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 43. By Company, Japan Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 44. By Drug Class, Japan Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 45. By Distribution Channel, Japan Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 46. South Korea Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 47. By Company, South Korea Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 48. By Drug Class, South Korea Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 49. By Distribution Channel, South Korea Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 50. Southeast Asia Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 51. By Company, Southeast Asia Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 52. By Drug Class, Southeast Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 53. By Distribution Channel, Southeast Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 54. India Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 55. By Company, India Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 56. By Drug Class, India Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 57. By Distribution Channel, India Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 58. Middle East & Asia Rare Kidney Diseases Treatment Revenue, 2019-2030, (US$ Million)

Figure 59. By Company, Middle East & Asia Rare Kidney Diseases Treatment Market Share, 2019-2024

Figure 60. By Drug Class, Middle East & Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 61. By Distribution Channel, Middle East & Asia Rare Kidney Diseases Treatment Revenue Market Share, 2022 VS 2029

Figure 62. Research Methodology

Figure 63. Breakdown of Primary Interviews

Figure 64. Bottom-up Approaches

Figure 65. Top-down Approaches